176 related articles for article (PubMed ID: 1605607)
1. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses.
Shigeta S; Mori S; Baba M; Ito M; Honzumi K; Nakamura K; Oshitani H; Numazaki Y; Matsuda A; Obara T
Antimicrob Agents Chemother; 1992 Feb; 36(2):435-9. PubMed ID: 1605607
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.
De Clercq E; Cools M; Balzarini J; Snoeck R; Andrei G; Hosoya M; Shigeta S; Ueda T; Minakawa N; Matsuda A
Antimicrob Agents Chemother; 1991 Apr; 35(4):679-84. PubMed ID: 2069373
[TBL] [Abstract][Full Text] [Related]
3. A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho- and paramyxoviruses.
Mori S; Watanabe W; Shigeta S
Tohoku J Exp Med; 1995 Dec; 177(4):315-25. PubMed ID: 8928191
[TBL] [Abstract][Full Text] [Related]
4. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.
Leyssen P; Balzarini J; De Clercq E; Neyts J
J Virol; 2005 Feb; 79(3):1943-7. PubMed ID: 15650220
[TBL] [Abstract][Full Text] [Related]
5. 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes.
Balzarini J; Lee CK; Schols D; De Clercq E
Biochem Biophys Res Commun; 1991 Jul; 178(2):563-9. PubMed ID: 1650194
[TBL] [Abstract][Full Text] [Related]
6. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro.
Dal Pozzo F; Galligioni V; Vaccari F; Gallina L; Battilani M; Scagliarini A
Res Vet Sci; 2010 Apr; 88(2):339-44. PubMed ID: 19781726
[TBL] [Abstract][Full Text] [Related]
7. Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.
Wyde PR; Moore-Poveda DK; De Clercq E; Neyts J; Matsuda A; Minakawa N; Guzman E; Gilbert BE
Antimicrob Agents Chemother; 2000 May; 44(5):1146-52. PubMed ID: 10770743
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of infectious pancreatic necrosis virus (IPNV) replication.
Jashés M; González M; López-Lastra M; De Clercq E; Sandino A
Antiviral Res; 1996 Mar; 29(2-3):309-12. PubMed ID: 8739609
[TBL] [Abstract][Full Text] [Related]
9. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
Ölschläger S; Neyts J; Günther S
Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Winslow S; Hoopes J; Li JK; Lee J; Carson DA; Cottam HB; Sidwell RW
Antiviral Res; 2006 Aug; 71(1):53-63. PubMed ID: 16621037
[TBL] [Abstract][Full Text] [Related]
11. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Balzarini J; Karlsson A; Wang L; Bohman C; Horská K; Votruba I; Fridland A; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1993 Nov; 268(33):24591-8. PubMed ID: 7901217
[TBL] [Abstract][Full Text] [Related]
12. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.
Kirsi JJ; North JA; McKernan PA; Murray BK; Canonico PG; Huggins JW; Srivastava PC; Robins RK
Antimicrob Agents Chemother; 1983 Sep; 24(3):353-61. PubMed ID: 6615611
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives.
Minakawa N; Matsuda A
Curr Med Chem; 1999 Jul; 6(7):615-28. PubMed ID: 10390604
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication.
Jashés M; Mlynarz G; De Clercq E; Sandino AM
Antiviral Res; 2000 Jan; 45(1):9-17. PubMed ID: 10774586
[TBL] [Abstract][Full Text] [Related]
15. Antivirally active ribavirin analogues--4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling.
Krajczyk A; Kulinska K; Kulinski T; Hurst BL; Day CW; Smee DF; Ostrowski T; Januszczyk P; Zeidler J
Antivir Chem Chemother; 2014 Jan; 23(4):161-71. PubMed ID: 23538746
[TBL] [Abstract][Full Text] [Related]
16. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents.
Watanabe W; Konno K; Ijichi K; Inoue H; Yokota T; Shigeta S
J Virol Methods; 1994 Jul; 48(2-3):257-65. PubMed ID: 7989442
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.
Kirsi JJ; McKernan PA; Burns NJ; North JA; Murray BK; Robins RK
Antimicrob Agents Chemother; 1984 Oct; 26(4):466-75. PubMed ID: 6517540
[TBL] [Abstract][Full Text] [Related]
18. Biochemistry and clinical applications of ribavirin.
Gilbert BE; Knight V
Antimicrob Agents Chemother; 1986 Aug; 30(2):201-5. PubMed ID: 2876677
[No Abstract] [Full Text] [Related]
19. Effects of protease inhibitors on replication of various myxoviruses.
Hosoya M; Matsuyama S; Baba M; Suzuki H; Shigeta S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1432-6. PubMed ID: 1510439
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition of subacute sclerosing panencephalitis virus by the antiviral agent ribavirin.
Murphy MF
J Infect Dis; 1978 Aug; 138(2):249-51. PubMed ID: 79625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
